公开(公告)号：US20150148296A1

公开(公告)日：2015-05-28

申请号：US14404222

申请日：2013-05-17

申请人： KINKI UNIVERSITY ,  ASAHI KASEI PHARMA CORPORATION

发明人： Atsufumi Kawabata ,  Hideaki Suzuki

IPC分类号： A61K38/36 ,  A61K45/06

摘要： A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.

摘要翻译： 用于预防性和/或治疗性治疗周围神经性疼痛的药物，所述外周神经性疼痛例如由抗癌剂治疗引起的异常性疼痛，其包含血栓调节蛋白作为活性成分。

公开(公告)号：US09034823B2

公开(公告)日：2015-05-19

申请号：US14283976

申请日：2014-05-21

申请人： ASAHI KASEI PHARMA CORPORATION

发明人： Kazuhisa Tsuruta ,  Yoshikazu Aoki ,  Yutaka Osawa ,  Inder Kaul

IPC分类号： A61K38/36 ,  A61K38/57 ,  A61K38/17 ,  A61K38/00 ,  C12N15/09

CPC分类号： A61K38/366 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/177 ,  A61K38/57 ,  C12N15/09

摘要： A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.

摘要翻译： 一种用于治疗和/或改善伴有一种或多种器官功能障碍的严重败血症患者的败血症的药物，其中从所述患者获得的血浆样本的国际标准化比率（INR）大于1.4，其包括 血栓调节素作为活性成分。

公开(公告)号：US08952137B2

公开(公告)日：2015-02-10

申请号：US13557645

申请日：2012-07-25

申请人： Susumu Ohigashi

发明人： Susumu Ohigashi

IPC分类号： A23J1/00 ,  C07K1/18 ,  C07K14/745 ,  C07K1/16

CPC分类号： C07K1/18 ,  C07K1/165 ,  C07K14/7455

摘要： A method is provided for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that is generated under acidic conditions, which comprises: subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein the gradient is a salt concentration gradient, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction.

摘要翻译： 提供了一种生产可溶性血栓调节蛋白的方法，其基本上不含有在酸性条件下产生的可溶性血栓调节蛋白的变性产物，其包括：将可溶性血栓调节蛋白的材料经受阴离子交换剂或羟基磷灰石; 并进行线性梯度洗脱，逐步梯度洗脱或梯度洗脱，其中线性梯度洗脱与可分离可溶性血栓调节蛋白的变性产物的分离条件下逐步梯度洗脱组合，其中梯度为盐浓度梯度， 以获得含有可溶性血栓调节蛋白的洗脱级分，该可溶性血栓调节蛋白基本上不含可溶性血栓调节素的变性产物，（a）预先确认了级分的位置之后，或（b）确认洗脱级分。

公开(公告)号：US20140088014A1

公开(公告)日：2014-03-27

申请号：US14116483

申请日：2012-05-31

申请人： Fumihide Nishio ,  Takuji Maejima ,  Yoshiro Mitome

发明人： Fumihide Nishio ,  Takuji Maejima ,  Yoshiro Mitome

IPC分类号： A61K9/19 ,  A61K38/29

CPC分类号： C07K14/635 ,  A61K9/19 ,  A61K38/29 ,  B65B55/10 ,  B65B55/12 ,  B65B63/08 ,  G01N30/7233

摘要： [Problem] Provided is a freeze-dried preparation containing high-purity PTH peptide and a method for the production thereof. Also provided is a test method for PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like.[Solution] In the present invention, the presence of PTH analogs produced during the manufacturing process of a freeze-dried preparation containing PTH peptide was confirmed. The production of these PTH analogs was also discovered to be markedly prevented or reduced by controlling exposure of the solution containing PTH peptide and the like to air environments within a pharmaceutical production facility.

摘要翻译： [问题]提供含有高纯度PTH肽的冷冻干燥制剂及其制造方法。 还提供了PTH类似物的测试方法，以确认含有PTH肽的冷冻干燥制剂的纯度等。 [解决方案]在本发明中，确认了在含有PTH肽的冷冻干燥制剂的制造过程中产生的PTH类似物的存在。 通过控制含有PTH肽等的溶液暴露于药物生产设备内的空气环境，也发现了这些PTH类似物的生产被显着地防止或减少。

公开(公告)号：US08258269B2

公开(公告)日：2012-09-04

申请号：US12532598

申请日：2008-03-21

申请人： Susumu Ohigashi

发明人： Susumu Ohigashi

IPC分类号： A23J1/00

CPC分类号： C07K1/18 ,  C07K1/165 ,  C07K14/7455

摘要： It is an object of the present invention to obtain a soluble thrombomodulin substantially not containing a denatured product of soluble thrombomodulin that may be generated under acidic conditions. The present invention provides a method for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that may be generated under acidic conditions, from a soluble thrombomodulin-containing material that contains or is suspected to contain the denatured product of the soluble thrombomodulin, which comprises; a step of subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and a step of carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein said gradient is a gradient of salt concentration, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction.

摘要翻译： 本发明的目的是获得在酸性条件下可能产生的可溶性血栓调节蛋白基本上不含有变性产物的可溶性血栓调节蛋白。 本发明提供一种生产可溶性血栓调节蛋白的方法，所述溶解性血栓调节蛋白基本上不含有可能在酸性条件下产生的可溶性血栓调节蛋白的变性产物，所述可溶性血栓调节蛋白含有含有或怀疑含有可溶性血栓调节蛋白的变性产物的可溶性血栓调节蛋白的材料， 包括 使含有可溶性血栓调节蛋白的材料经受阴离子交换剂或羟基磷灰石的步骤; 以及进行线性梯度洗脱，逐步梯度洗脱或梯度洗脱的步骤，其中线性梯度洗脱与可分离可溶性血栓调节蛋白的变性产物的分离条件下逐步梯度洗脱组合，其中所述梯度为梯度 的盐浓度，从而得到含有可溶性血栓调节蛋白的洗脱级分，其基本上不含有可溶性血栓调节素的变性产物，（a）在部分的位置以前已被确认的情况下，或（b）在确认洗脱的同时 分数。

公开(公告)号：US08232292B2

公开(公告)日：2012-07-31

申请号：US12216257

申请日：2008-07-01

申请人： Hitoshi Kida ,  Koki Matsubara ,  Shunsuke Kaneko ,  Yoshihito Kanzawa

发明人： Hitoshi Kida ,  Koki Matsubara ,  Shunsuke Kaneko ,  Yoshihito Kanzawa

IPC分类号： A61K31/47 ,  C07D401/02

CPC分类号： C07D401/12

摘要： (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.

摘要翻译： （S）-1-（4-氯-5-异喹啉磺酰基）-3-（甲基氨基）吡咯烷一盐酸盐及其结晶，以及上述一盐酸盐的结晶，在一个或多个位置上具有主峰或峰 由粉末X射线衍射光谱中的2和等级为13.9°，21.5°，21.7°，22.4°，22.8°，24.5°和35.0°的位置组成，其作为预防药物的活性成分具有优异的性质 和/或治疗性青光眼等。

公开(公告)号：US08026075B2

公开(公告)日：2011-09-27

申请号：US12977874

申请日：2010-12-23

申请人： Fumitomo Odawara

发明人： Fumitomo Odawara

IPC分类号： G01N33/53 ,  G01N31/00

CPC分类号： C07B63/04 ,  C12Q1/008

摘要： Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme.

摘要翻译： 公开了作为抑制磷酸化辅酶的脱磷酸化反应的物质的糖和/或糖醇。 还公开了一种稳定磷酸化辅酶的方法，其特征在于至少具有抑制磷酸化辅酶的去磷酸化反应与磷酸化辅酶共存的物质。

公开(公告)号：US08008506B2

公开(公告)日：2011-08-30

申请号：US12569295

申请日：2009-09-29

申请人： Seiji Nakano ,  Taisuke Iwanami ,  Kei Yamanishi ,  Yasuhiro Wada ,  Akifumi Morimoto

发明人： Seiji Nakano ,  Taisuke Iwanami ,  Kei Yamanishi ,  Yasuhiro Wada ,  Akifumi Morimoto

IPC分类号： C07D231/56 ,  A61K31/416

CPC分类号： C07D231/56 ,  A61K31/416 ,  A61K31/695 ,  C07D303/08 ,  C07D405/04

摘要： Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have β3 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

摘要翻译： 提供由下式（A-1）和式（1）表示的化合物或其盐。 式（A-1）和式（1）的化合物或其盐具有β肾上腺素能受体激动剂活性，因此可用作糖尿病，肥胖症，高脂血症，抑郁症，由胆结石引起的疾病或 胆汁过度运动，消化道多动症，间质性膀胱炎，膀胱过度活动性膀胱或尿失禁引起的疾病，或伴随泪液减少的疾病的治疗和预防剂。

公开(公告)号：US07960392B2

公开(公告)日：2011-06-14

申请号：US12502529

申请日：2009-07-14

申请人： Masakazu Atobe ,  Kenji Naganuma ,  Akifumi Morimoto ,  Teruki Kobayashi

发明人： Masakazu Atobe ,  Kenji Naganuma ,  Akifumi Morimoto ,  Teruki Kobayashi

IPC分类号： C07D401/14 ,  C07D277/00 ,  A61K31/4436 ,  A61K31/427

CPC分类号： C07D277/20 ,  A61K31/427 ,  A61K31/44 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14 ,  C07D491/048

摘要： Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical agent for prophylaxis and/or treatment of an overactive bladder, for example. Furthermore, they are useful as an effective component of a pharmaceutical agent for the prophylaxis and/or treatment of symptoms including frequent urination, urinary urgency and urinary incontinence.

摘要翻译： 提供由下式（1）表示的含氮杂环化合物。 当化合物或其盐施用于人或动物时，其化合物或其盐具有强的EP1拮抗活性，并且它们可用作预防和/或治疗膀胱过度活动症的药物的有效成分。 此外，它们可用作用于预防和/或治疗包括频尿，尿急和尿失禁的症状的药剂的有效成分。

公开(公告)号：US07919460B2

公开(公告)日：2011-04-05

申请号：US11905082

申请日：2007-09-27

申请人： Satoru Matayoshi

发明人： Satoru Matayoshi

IPC分类号： A61K38/23

CPC分类号： A61K38/23

摘要： The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active ingredient. The present invention is also intended to provide a method for preventing the onset of post-stroke RSD, comprising administering natural calcitonin or a calcitonin derivative and use of natural calcitonin or a calcitonin derivative for producing an agent for preventing the onset of post-stroke RSD.

摘要翻译： 本发明旨在提供对中风后RSD具有优异的预防效果的新型药剂。 本发明提供了防止中风后RSD发作的药剂，其包含天然降钙素或降钙素衍生物作为有效成分。 本发明还旨在提供一种防止中风后RSD发作的方法，包括施用天然降钙素或降钙素衍生物，以及使用天然降钙素或降钙素衍生物制备用于预防中风后RSD发作的药剂 。